8-K: Relay Therapeutics Reports Full Year 2023 Financial Results and Clinical Program Updates

Relay Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting progress in clinical programs and a strong cash position to fund operations into the second half of 2026.

Summary

• Relay Therapeutics reported its financial results for the fourth quarter and full year 2023.
• The company's cash, cash equivalents, and investments totaled approximately $750 million as of December 31, 2023, compared to approximately $1 billion at the end of 2022.
• Relay Therapeutics expects its current cash to fund operations into the second half of 2026.
• Full year 2023 revenue was $25.5 million, up from $1.4 million in 2022, primarily due to milestone payments from a collaboration agreement.
• Research and development expenses increased to $330 million for the full year 2023, compared to $246.4 million in 2022.
• The net loss for the full year 2023 was $342 million, or $2.79 per share, compared to a net loss of $290.5 million, or $2.59 per share, in 2022.
• The company completed enrollment in the initial dose expansion cohort of RLY-2608 and initiated additional dose expansion cohorts.
• Relay Therapeutics also initiated a triplet combination study of RLY-2608 with fulvestrant and ribociclib.
• The company plans to disclose at least one new program from its Dynamo platform later in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong cash position, progress in clinical programs, and the potential of the Dynamo platform, although the increased net loss and R&D expenses temper the overall outlook.

Positives

• Relay Therapeutics has a strong cash position of approximately $750 million, providing a runway into the second half of 2026.
• The company's revenue increased significantly year-over-year, primarily due to milestone payments.
• The clinical development of RLY-2608 is progressing with the completion of enrollment in the initial dose expansion cohort and the initiation of additional cohorts.
• The initiation of the RLY-2608 triplet combination study is a positive step in expanding the potential of the drug.
• The Dynamo platform continues to be productive, with plans to disclose at least one new program in 2024.

Negatives

• The company experienced a net loss of $342 million for the full year 2023, an increase from $290.5 million in 2022.
• Research and development expenses increased significantly to $330 million for the full year 2023.
• The company has deprioritized further clinical development of RLY-5836.

Risks

• The company's future results are subject to risks associated with global economic uncertainty, geopolitical instability, and public health epidemics.
• There is a risk of delays or pauses in current or planned clinical trials.
• Preliminary results from pre-clinical or clinical trials may not be predictive of future results.
• The company faces risks related to demonstrating the safety and efficacy of its drug candidates.
• There are risks associated with obtaining, maintaining, and protecting intellectual property.

Future Outlook

Relay Therapeutics expects its current cash to fund operations into the second half of 2026 and anticipates several clinical data updates and a new program disclosure in 2024.

Management Comments

• We made important progress across our portfolio during 2023, advancing multiple clinical programs and continuing to invest significantly in our research engine – the Dynamo platform, said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
• We are very pleased with the RLY-2608 data disclosed to-date and how its clinical profile continued to mature throughout last year.
• Our clinical team is focused on advancing this program in the near term in both a doublet and a triplet combination, and we look forward to sharing additional data in the second half of 2024.
• Our Dynamo platform continues to demonstrate precision and productivity with each target we’ve chosen to-date, and we are excited to disclose at least one new program that has come out of it later this year, which is being designed to have first-in-class potential.

Industry Context

This announcement reflects the ongoing trend in the biotech industry of focusing on precision medicine and advancing clinical programs, while also managing cash burn and prioritizing research and development. The company's focus on its Dynamo platform and the development of novel therapies aligns with the industry's push for innovative treatments.

Comparison to Industry Standards

• Relay Therapeutics' cash runway into the second half of 2026 is relatively strong compared to many clinical-stage biotech companies, which often have cash runways of 1-3 years.
• The increase in R&D expenses is typical for a company advancing multiple clinical programs, similar to companies like Arcus Biosciences and Blueprint Medicines.
• The company's focus on a platform approach with Dynamo is similar to companies like Schrödinger and Recursion Pharmaceuticals, which use computational methods for drug discovery.
• The initiation of a triplet combination study for RLY-2608 is a strategy seen in other oncology companies, such as Novartis and Roche, to improve efficacy and overcome resistance.

Stakeholder Impact

• Shareholders may be encouraged by the strong cash position and clinical progress, but concerned about the increasing net loss.
• Employees may be positively impacted by the company's continued investment in research and development.
• Patients may benefit from the potential development of new therapies.
• Creditors are likely to view the company's financial stability favorably.

Next Steps

• Relay Therapeutics will provide a data update for RLY-2608 + fulvestrant in the second half of 2024.
• Initial safety data for the RLY-2608 + fulvestrant + ribociclib triplet combination will be released in the second half of 2024.
• A tumor agnostic data and regulatory update for Lirafugratinib is expected in the second half of 2024.
• The company plans to disclose new program(s) from its pre-clinical pipeline in 2024.

Key Dates

Keywords

Relay Therapeutics, RLY-2608, Lirafugratinib, PI3K inhibitor, breast cancer, clinical trials, Dynamo platform, precision medicine, oncology, financial results